炎性指标在非小细胞肺癌患者预后中的临床意义

doi:10.3969/j.issn.1004-583X.2022.07.016

摘要/Abstract

摘要：

在全球范围内,非小细胞肺癌是一种发病率和死亡率均较高的常见恶性肿瘤。随着诊疗水平的不断进步,其死亡率虽有所下降,但预后仍较差。因此,积极探寻可靠的预后指标尤为重要。既往研究表明,肿瘤的发生发展与炎症相关。本研究通过对常见的炎性指标对非小细胞肺癌预后的影响进行综述,旨在为临床诊治提供依据。

关键词: 癌, 非小细胞肺, 炎症, 免疫, 预后

中图分类号:

R730.26

轩晓倩, 赵君慧, 杨小茜. 炎性指标在非小细胞肺癌患者预后中的临床意义[J]. 临床荟萃, 2022, 37(7): 663-667.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.07.016

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I7/663

参考文献 46

[1]	Sung H, Ferlay J, Rebecca LS, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660 URL
[2]	Ozkan EE, Kaymak Cerkesli ZA, Erdogan M. Predictive value of immune-inflammation indices in metabolic response and outcome after curative radiotherapy in patients with non-small cell lung cancer[J]. Clin Respir J, 2020, 14(9):849-856. doi: 10.1111/crj.13217 pmid: 32421891
[3]	郑开文. 炎症标志物在恶性肿瘤患者预后预测中应用效力的探索[D]. 长春: 吉林大学, 2020.
[4]	Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203):436-444. doi: 10.1038/nature07205 URL
[5]	Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144(5):646-674. doi: 10.1016/j.cell.2011.02.013 pmid: 21376230
[6]	Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow?[J]. Lancet, 2001, 357(9255):539-545. doi: 10.1016/S0140-6736(00)04046-0 pmid: 11229684
[7]	Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144(5):646-674. doi: 10.1016/j.cell.2011.02.013 pmid: 21376230
[8]	Matsubara T, Takamori S, Haratake N, et al. Identifification of the best prognostic marker among immunonutritional parameters using serum C-reactive protein and albumin in Non-small cell lung cancer[J]. Ann Surg Oncol, 2021, 28(6):3046-3054. doi: 10.1245/s10434-020-09230-x pmid: 33084992
[9]	马书梅. 2289例肺癌患者临床流行病学特征分析[D]. 济宁: 济宁医学院, 2020.
[10]	吴丽, 郑玲. 炎性复合指标与非小细胞肺癌预后关系的研究进展[J]. 现代肿瘤医学, 2019, 27(2):342-345.
[11]	Yee PP, Wei Y, Kim SY, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression[J]. Nat Commun, 2020, 11(1):5424. doi: 10.1038/s41467-020-19193-y pmid: 33110073
[12]	张洁, 张小陆, 于杰, 等. 治疗前中性粒细胞与淋巴细胞比值对小细胞肺癌患者预后的意义[J]. 河北医科大学学报, 2019, 40(3):292-295.
[13]	Weng J, Huang J, Yu W, et al. Combination of albumin concentration and neutrophil-to-lymphocyte ratio for predicting overall survival of patients with non-small cell lung cancer[J]. J Thorac Dis, 2021, 13(9):5508-5516. doi: 10.21037/jtd-21-1320 pmid: 34659817
[14]	Palomar-Abril V, Soria-Comes T, Campos ST, et al. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy[J]. Clin Transl Oncol, 2020, 22(12):2333-2340. doi: 10.1007/s12094-020-02396-6 URL
[15]	Fujimoto A, Toyokawa G, Koutake Y, et al. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer[J]. Thorac Cancer, 2021, 12(15):2198-2204. doi: 10.1111/1759-7714.14063 URL
[16]	Gavrilov S, Zhudenkov K, Helmlinger G, et al. Longitudinal tumor size and neutrophil-to-lymphocyte ratio are prognostic biomarkers for overall survival in patients with advanced Non-small cell lung cancer treated with durvalumab[J]. CPT Pharmacometrics Syst Pharmacol, 2021, 10(1):67-74. doi: 10.1002/psp4.12578 URL
[17]	陈晓博, 王倩, 李庆霞, 等. 系统性免疫炎症指数与非小细胞肺癌患者预后关系的研究进展[J]. 肿瘤防治研究杂志, 2021, 48(6):652-656.
[18]	Trac N, Chen LY, Zhang A, et al. CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation[J]. J Control Release, 2021, 329:614-623. doi: 10.1016/j.jconrel.2020.09.054 URL
[19]	Casanova-Acebes M, Dalla E, Leader AM. et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells[J]. Nature, 2021, 595(7868):578-584. doi: 10.1038/s41586-021-03651-8 URL
[20]	Yuan C, Li N, Mao X, et al. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort[J]. Thorac Cancer, 2017, 8(4):350-358. doi: 10.1111/1759-7714.12454 pmid: 28544400
[21]	张利平. 单核细胞与淋巴细胞比率、纤维蛋白原与白蛋白比率在肺癌诊断中的作用[D]. 南昌: 南昌大学, 2021.
[22]	Gao Y, Zhang H, Li Y, et al. Preoperative pulmonary function correlates with systemic inflammatory response and prognosis in patients with non-small cell lung cancer:results of a single institution retrospective study[J]. Oncotarget, 2017, 8(16):27489-27501. doi: 10.18632/oncotarget.14225 URL
[23]	Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells[J]. Nature, 2016, 529(7586):298-306. doi: 10.1038/nature17038 URL
[24]	徐小峰, 戴宏宇, 乔建兵,等. 外周血NLR和PLR评估晚期非小细胞肺癌一线含铂双药化疗疗效和预后的价值[J]. 现代肿瘤医学, 2020, 28(15):2627-2631.
[25]	Łochowski M, Chałubińska-Fendler J, Zawadzka I, et al. The prognostic significance of preoperative platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients operated for non-small cell lung cancer[J]. Cancer Manag Res, 2021, 13:7795-7802. doi: 10.2147/CMAR.S317705 pmid: 34675674
[26]	Liu KJ, Jiang GM, Fang NX, et al. Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer[J]. J Int Med Res, 2020, 48(12):300060520980205.
[27]	谢剑华, 刘苗苗, 彭丽丽, 等. 系统免疫炎症营养指数与非手术治疗老年非小细胞肺癌患者预后的关系研究[J]. 中国全科医学, 2022, 25(17):2082-2089. doi: 10.12114/j.issn.1007-9572.2022.0102
[28]	Coutu BG, Johnson KC, Bhirud A, et al. Systemic immune-inflammatory index association with survival in patients undergoing trimodality therapy for lung cancer[J]. Oncology, 2022, 100(5):247-256. doi: 10.1159/000520989 URL
[29]	李影, 刘苗苗, 何严璐琦, 等. 治疗前系统免疫-炎症指数、纤维蛋白原对非小细胞肺癌预后的评估价值[J]. 河北医科大学学报, 2021, 42(5):514-519.
[30]	Zhang Y, Chen B. Prognostic value of the advanced lung cancer inflammation index in patients with lung cancer:A meta-analysis[J]. Dis Markers, 2019, 2019:2513026.
[31]	Mandaliya H, Jones M, Oldmeadow C, et al. Prognostic biomarkers in stage IV non-small cell lung cancer(NSCLC):Neutrophil to lymphocyte ratio(NLR), lymphocyte to monocyte ratio(LMR), platelet to lymphocyte ratio(PLR) and advanced lung cancer inflammation index(ALI)[J]. Transl Lung Cancer Res, 2019, 8(6):886-894. doi: 10.21037/tlcr.2019.11.16 URL
[32]	Kobayashi S, Karube Y, Inoue T, et al. Advanced lung cancer inflammation index predicts outcomes of patients with pathological stage IA lung adenocarcinoma following surgical resection[J]. Ann Thorac Cardiovasc Surg, 2019, 25(2):87-94. doi: 10.5761/atcs.oa.18-00158 URL
[33]	Yamamoto M, Saito H, Uejima C, et al. Prognostic value of the combination of pre-and postoperative C-reactive protein in colorectal cancer patients[J]. Surg Today, 2018, 48(11):986-993. doi: 10.1007/s00595-018-1689-9 pmid: 29946884
[34]	Rielland M, Cantor DJ, Graveline R, et al. Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression[J]. J Clin Invest, 2014, 124(5):2125-2135. doi: 10.1172/JCI72619 pmid: 24691445
[35]	刘丽荣, 侯芳芳, 张海波,等. 血清C反应蛋白与晚期非小细胞肺癌患者化疗疗效的相关性[J]. 中国临床研究, 2020, 33(6):778-780.
[36]	廖浪霞, 严达尊, 吴柱标, 等. 肺癌临床分期与C反应蛋白联合四项肿瘤标志物的相关性研究[J]. 实用医技杂志, 2018, 25(4):380-382.
[37]	Leung EY, Scott HR, McMillan DC. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer[J]. J Thorac Oncol, 2012, 7(4):655-662. doi: 10.1097/JTO.0b013e318244ffe1 pmid: 22425914
[38]	Fan H, Shao ZY, Xiao YY, et al. Comparison of the Glasgow prognostic score(GPS) and the modified Glasgow prognostic score(mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2016, 142(6):1285-1297. doi: 10.1007/s00432-015-2113-0 URL
[39]	Takamori S, Takada K, Shimokawa M, et al. Clinical utility of pretreatment glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors[J]. Lung Cancer, 2021, 152:27-33. doi: 10.1016/j.lungcan.2020.11.026 pmid: 33341085
[40]	Kishi T, Matsuo Y, Ueki N, et al. Pretreatment modified glasgow prognostic score predicts clinical outcomes after stereotactic body radiation therapy for early-stage non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 92(3):619-626. doi: 10.1016/j.ijrobp.2015.02.018 URL
[41]	王彦, 吴砚铭, 王彦文, 等. C反应蛋白/白蛋白比值与肺癌患者预后关系的meta分析[J]. 华西医学杂志, 2019, 34(1):50-57.
[42]	Araki T, Tateishi K, Sonehara K, et al. Clinical utility of the C-reactive Protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab[J]. Thorac Cancer, 2021, 12(5):603-612. doi: 10.1111/1759-7714.13788 pmid: 33434414
[43]	Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer[J]. Asia Pac J Clin Oncol, 2018, 14(6):402-409. doi: 10.1111/ajco.13055 URL
[44]	王晓兰, 韩伟, 王莹. 营养免疫与系统炎症参数在非小细胞肺癌患者中的预后意义[J]. 肿瘤代谢与营养电子杂志, 2021, 8(5):519-524.
[45]	Sun K, Chen S, Xu J, et al. The prognostic significance of the prognostic nutritional index in cancer: A systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 2014, 140:1537-1549. doi: 10.1007/s00432-014-1714-3 pmid: 24878931
[46]	Bozkaya Y, Köstek O, Sakin A, et al. Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?[J]. Support Care Cancer, 2020, 28(5):2273-2282. doi: 10.1007/s00520-019-05055-x pmid: 31471631

炎性指标在非小细胞肺癌患者预后中的临床意义

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 46

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张晓璐, 李红山. 自身免疫性肝炎发病机制研究进展——聚焦“肠道菌群与免疫系统相互作用”[J]. 临床荟萃, 2024, 39(2): 177-182.
[2]	赵旭辉, 黄小敏, 达德转, 许焱, 崔晓东, 李红玲. 基于生物信息学筛选影响胃癌患者预后的糖酵解相关基因[J]. 临床荟萃, 2024, 39(1): 20-29.
[3]	刘丽丽, 袁宇婷, 赖耿良, 田川, 蓝翔, 叶中绿. 儿童急性淋巴细胞白血病第15天微小残留与预后的关系[J]. 临床荟萃, 2024, 39(1): 47-52.
[4]	宋佳亮, 蒋英杰, 孔瑞娜, 蔡青, 高洁. 以IgE和嗜酸粒细胞升高伴多发淋巴结肿大为主要表现的IgG4相关性疾病1例报告[J]. 临床荟萃, 2024, 39(1): 57-60.
[5]	崔兰丹, 杨春燕. 脓毒症患者甲状腺激素的变化特点及研究进展[J]. 临床荟萃, 2024, 39(1): 70-74.
[6]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[7]	王涛, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗磷脂酶A2受体抗体与特发性膜性肾病的相关性[J]. 临床荟萃, 2023, 38(7): 606-612.
[8]	李阳, 默峰, 辛志飞, 王倩, 邓新娜. 特殊临床表现多系统免疫相关不良事件1例[J]. 临床荟萃, 2023, 38(7): 633-637.
[9]	裴红运, 文洁, 山凤莲. 结核病患者淋巴细胞程序性细胞死亡受体-1表达变化的研究进展[J]. 临床荟萃, 2023, 38(7): 659-662.
[10]	高秦宇, 包蓓艳, 金燕, 赵宇. IgA肾病合并抑郁状态患者的临床特征和预后影响因素分析[J]. 临床荟萃, 2023, 38(6): 510-515.
[11]	孙星星, 林海. 儿童重症肺炎的免疫功能变化及预后危险因素[J]. 临床荟萃, 2023, 38(6): 521-525.
[12]	程婷婷, 齐彩英, 张雪莲, 肖梦, 隋伟行, 李小燕, 刘建英. 重症肺炎支原体肺炎与血清IgE和C反应蛋白水平的相关性及临床特征[J]. 临床荟萃, 2023, 38(5): 433-437.
[13]	贺翔渝, 潘燕, 张小林. 血清脂蛋白相关磷脂酶A2水平与急性缺血性脑卒中病情及预后的关系[J]. 临床荟萃, 2023, 38(4): 315-318.
[14]	冷婉铜, 陶洁. 多发性骨髓瘤患者治疗后发生静脉血栓栓塞的危险因素[J]. 临床荟萃, 2023, 38(4): 340-345.
[15]	杨金强, 张仁敏. 降钙素原与血小板比值评估发热伴血小板减少综合征预后的价值[J]. 临床荟萃, 2023, 38(4): 346-351.